Arcutis Biotherapeutics Inc Forecast, price target & analysts
Arcutis Biotherapeutics Inc Target price 2025 - Analyst rating & recommendation
Arcutis Biotherapeutics Inc Classifications & Recommendation:
Arcutis Biotherapeutics Inc Price Target
| Target Price | $20.43 |
| Price | $14.81 |
| Potential |
37.94%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Arcutis Biotherapeutics Inc 2026 .
The average Arcutis Biotherapeutics Inc target price is $20.43.
This is
37.94%
register free of charge
$29.00
95.81%
register free of charge
$15.00
1.28%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Arcutis Biotherapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Arcutis Biotherapeutics Inc stock has an average upside potential 2026 of
37.94%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 196.54 | 302.32 |
| 229.71% | 53.82% | |
| EBITDA Margin | -64.01% | -34.03% |
| 84.05% | 46.83% | |
| Net Margin | -69.56% | -17.44% |
| 90.69% | 74.93% |
7 Analysts have issued a sales forecast Arcutis Biotherapeutics Inc 2025 . The average Arcutis Biotherapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Arcutis Biotherapeutics Inc 2025 . The average Arcutis Biotherapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Arcutis Biotherapeutics Inc Analysts have issued a net profit forecast 2025. The average Arcutis Biotherapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.16 | -0.45 |
| 69.31% | 61.21% | |
| P/E | negative | |
| EV/Sales | 5.56 |
4 Analysts have issued a Arcutis Biotherapeutics Inc forecast for earnings per share. The average Arcutis Biotherapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Arcutis Biotherapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Arcutis Biotherapeutics Inc...
Current Arcutis Biotherapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Jefferies |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Feb 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Jefferies:
Locked
➜
Locked
|
Mar 11 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Feb 24 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Feb 10 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
